ArticleFrontiers in immunology2024

Case report: tumefactive demyelinating lesions after the second cycle of alemtuzumab in multiple sclerosis; immune cell profile and biomarkers.

Neus Rabaneda-Lombarte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.